Key facts
- FDA granted Priority Review for Bristol Myers Squibb's Camzyos (mavacamten).
- The application is for symptomatic New York Heart Association class II-III obstructive hypertrophic cardiomyopathy (HCM).
- Priority Review designation means the drug may offer significant improvements in safety or effectiveness compared to available therapies.
Obstructive hypertrophic cardiomyopathy (oHCM) is a condition where the heart muscle thickens, making it harder for the heart to pump blood. Camzyos (mavacamten) is a medication designed to treat this condition. The Priority Review designation by the FDA suggests that Camzyos may represent a significant advancement in treating symptomatic oHCM.